Intercept Pharma (ICPT) Misses Q4 EPS by $1.10, Revenue Tops Views

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($4.84), $1.10 worse than the analyst estimate of ($3.74). Revenue for the quarter came in at $13 million versus the consensus estimate of $8.96 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Is the global equity rally broadening? UBS weighs in